We are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. In approximately three-and-a-half years, we have efficiently developed or in-licensed a pipeline of seven distinct programs by leveraging our hub-and-spoke business model. 

(Note: The IPO was upsized to 10 million shares, up from 8.33 million, and the price range was increased to $19 to $20, up from $17 to $19, in an S-1/A filing dated Jan. 6, 2021. The IPO is now expected to raise $195 million, if priced at the $19.50 mid-point of its newly increased range, compared with $149.94 million in estimated proceeds in its initial filing.)